Lv11
40 积分 2024-06-18 加入
Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies
11天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
30天前
已完结
Mechanisms of Cellular Avidity Regulation in CD2–CD58-Mediated T Cell Adhesion
1个月前
已完结
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: CombiningIn VitroExperiments with Systems Modeling
1个月前
已完结
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
1个月前
已完结
Repetitive Tumor Challenge Assay: An In Vitro Culture Assay to Evaluate Chimeric Antigen Receptor (CAR) T Cells for Repetitive Tumor Killing Potential
1个月前
已关闭
Emerging approaches for T cell-stimulating platform development
1个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
1个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control
1个月前
已完结
皖公网安备34019202002308
